ESPE Abstracts

Objective: The objective of this study is to determine the incidence of early neonatal hypoglycemia and to confirm potential risk factors.Study design: The study was conducted at a tertiary Medical Center in Qatar. between January 2018 and December 2019. First blood glucose concentrations of all infants admitted to the nursery were measured using a "point of care" analyzer (Accu-Chek). We recorded risk factors for hypoglycemia su...

Preterm babies born to non-diabetic mothers (INDM) who experience significant hypoglycemia may have postnatal growth abnormalities. This study evaluated the growth pattern from birth to the age of 2 years of 40 INDM who were born at or near term with significant hypoglycemia. Anthropometric measures (z scores) from birth, 2,4.6,12,18 and 2 years were measured in 40 INDM who presented with significant neonatal hypoglycemia (plasma value less than 20-25 mg/dl (1.1-1.4 mmol/l) th...

Objective: Infants born to mothers with glucose intolerance are at an increased risk of having growth abnormalities at birth and postnatally. This study evaluated the growth pattern of IDMs from birth to the age of 2 years.Research Design and Methods: Anthropometric measures (z scores) from birth, 2,4.6,12,18 and 2 years were measured in 60 IDM and 40 infants of non-diabetic mothers who presented with significant neonatal hypoglycemia (p...

Growth abnormalities at birth and abnormal postnatal pattern of weight gain have been reported in infants born to mothers with gestational diabetes (IDM). This study evaluated the growth pattern from birth to the age of 2 years of 60 IDMs who were born at or near term with significant hypoglycemia. Anthropometric measures (z scores) from birth, 2,4.6,12,18 and 2 years were measured in 60 IDM who presented with significant neonatal hypoglycemia (plasma value less than 20-25 mg/...

Background: Liquid nutritional supplements (ONS) are used successfully in the management of underweight infants and young children with undernutrition. However, their use in healthy old children and adolescents with underweight and/or poor weight gain has not been reported.Aim: This study describes the effect of OSN on nutritional outcomes in healthy underweight children and adolescents with no systemic illness.<p cl...

Introduction: Management of CAH presents unique challenges distinct from other forms of adrenal insufficiency. Higher doses of glucocorticoids are required to suppress adrenal androgen synthesis, which can lead to overtreatment. Steroid-associated adverse events (SAAE) include hypertension, hyperglycemia, and diabetes, overweight and obesity and short stature.Aim: The goal of this study was to assess the occurrence of st...

Introduction: Debate still exists about the safety of long-term use of prednisone (P) versus hydrocortisone (HC) for treating children with congenital adrenal hyperplasia -21OH D (CAH).Aim: To investigate the linear growth and weigh gain as well as metabolic component in children with CAH who were treated with either HC or P since early infancy for 5 years or more.Methods: Data of ...

Introduction: Prostaglandin E1 (PGE1) is a drug used for ductal patency in cyanotic congenital heart disease, We are reporting an infant with cortical hyperostosis secondary to prolonged use of PGE1, with typical and extensive radiological findings.Case Report: A 2-month-old girl, born at 37 weeks with APGAR scores of 9 & 10 at 1 & 5 min, and birth weight = 2.9 kg. She failed Critical Congenital Heart Defects Scr...

Abstract: Epidemiological and clinical data on LD in children and adolescents with T1DM are growing since 2010 because of the introduction of new insulin analogs and the use of insulin pumps (CSII). Many risk factors predispose to the occurrence of LD.Objectives and Methods: We performed an electronic search in PubMed, Google scholar and Web of Sciences to evaluate the global prevalence and possible risk factors of LD in...

Lipohypertrophy (LD) represents the most common cutaneous complication of insulin therapy worldwide. Epidemiological and clinical data on LD in children and adolescents with T1DM are growing since 2010 because of the introduction of new insulin analogs and the use of insulin pumps (CSII).Objectives and Methods: We performed an electronic search in PubMed, Google scholar and Web of Sciences to evaluate the global prevalence and possible r...